Granules India Ltd management interview: Granules India Reports Good Q2FY27 Earnings, But Margin Contracts QoQ | CNBC TV18
CNBC-TV18, 2026-11-03. Video: https://www.youtube.com/watch?v=hRDVVRH96iY
- Q2 performance: Granules India reported a 20% rise in revenue for the September quarter, with EBITDA growing around 21% and net profit jumping.
- Gagillapur inspection: Management said the 11 observations were mainly related to validations, with no data integrity, cross-contamination or facility issues. It was confident the worst case would be the status quo, with some pending applications delayed or not approved, rather than escalation to an import alert.
- Facility contribution: Gagillapur contributes less than 50% of overall revenue, mostly from legacy products. Some filings, including for critical products, have been transferred to the US site; growth is also coming from the US, Vizag and Hyderabad sites.
- North America outlook: North America was up nearly 14% this quarter, and management expects it to keep growing at a decent pace, with five launches coming in the next two quarters. It sees potential in control substances, complex generics and first-to-file products despite price pressure on some traditional products.
- Peptide CDMO: Granules is not participating in the GLP-1 opportunity; its peptide business serves innovator companies and is still nascent. Over the next 3-4-5 years, it expects revenues to cross 100 million Swiss francs.